Casa Physicians Alliance News
American Academy of Pediatrics Advises Parents to Choose Flu Shot for 2018-2019 Flu Season
AAP finds the inactivated influenza vaccine to be more consistently effective against most strains of flu, but says the nasal vaccine may be a last resort for kids who otherwise will not be vaccinated.
ITASCA (May 21, 2018) – The American Academy of Pediatrics will advise families to choose the inactivated influenza vaccine (IIV) -- the flu shot – when they vaccinate their children this fall. The decision was made by the AAP Board of Directors after reviewing data on the effectiveness of the flu shot compared with the nasal spray flu vaccine, which has not worked as well in recent flu seasons.
AAP will publish its formal policy statement on flu prevention and treatment in September. This decision was announced now because physicians are placing orders for vaccine.
"We really want to immunize as many children as we can against the flu with what we think will be the most effective vaccine. That's why we're recommending the flu shot," said Henry H. Bernstein, DO, MHCM, FAAP, associated editor of the AAP Red Book Online. "Influenza is unpredictable from season to season, which means vaccine effectiveness can vary by age, health status, and type of vaccine. Recent history has shown the injected form of the vaccine to be more consistent in protecting against most strains of flu virus."
The quadrivalent live attenuated influenza vaccine (LAIV4), which is given by intranasal spray to healthy patients ages 2 through 49 years, was a popular option for those reluctant to get a shot. However, in 2016, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) and the AAP reviewed data showing that it was not effective against H1N1 strains of the flu virus, and that it was less effective than expected against the H3N2 virus. They did not recommend it for the 2016-'17 and 2017-'18 seasons.
In February 2018, ACIP decided to make LAIV4 available for the 2018-2019 flu season, based on indirect study data from the manufacturer suggesting their new formulation would be effective, as well as a review of other published research.
However, upon review of the same data, the AAP recommends children receive the injectable form of the vaccine, which was shown to be more consistently effective against most strains of the flu virus over the past several flu seasons. For those children who would otherwise receive no flu vaccine, the AAP says the nasal spray vaccine can be given as a last resort, though it could leave them at higher risk for flu than if they had received the flu shot. The nasal spray vaccine is not recommended for children under 2 years or children with chronic medical conditions like asthma.
"The data reviewed showed that receiving the nasal spray vaccine is better than not getting any vaccine at all," said Flor Munoz, MD, FAAP, member of the AAP Committee on Infectious Diseases. "If you get the nasal spray vaccine, just be aware that, depending on the performance of the new vaccine formulation, there might be a chance you will not be fully protected against H1N1 strains of flu. The efficacy of this new formulation has not yet been determined."
The AAP recommends families talk with their pediatrician if they have any questions about their child's immunizations.
"The flu virus is common, but unpredictable. It can cause serious complications even in healthy children, which is why we strongly recommend annual flu vaccine for all people ages 6 months and older," said Dr. Bernstein. "Immunization is the best way to protect children from influenza." ###
The American Academy of Pediatrics is an organization of 66,000 primary care pediatricians, pediatric medical subspecialists and pediatric surgical specialists dedicated to the health, safety and well-being of infants, children, adolescents and young adults. For more information, visit www.aap.org and follow us on Twitter @AmerAcadPeds.
Posted by Shari Smith on 22nd May, 2018 | Comments | Trackbacks | Permalink
Tags: CASA Physicians Alliance, Vaccine Savings, Influenza, Seasonal Flu, Sanofi Pasteur Flu Vaccine, Discount Sanofi Vaccines, Schedule your Flu Shot, Vaccine Group, Influenza Vaccine, Healthcare Professional, Vaccine Discounts and Rebates, Savings on Pediatric Vaccines, Vaccine Group Purchasing Program, Quadrivalent Influenza Vaccine, Quadrivalent Flu Vaccine, Purchasing Program, Pediatric Vaccine, Sanofi Flu Partners Program, Medical Buying Group, Sanofi Pasteur
Guide to the Seasonal Flu for Seniors-National Council for Aging Care
The National Council for Aging Care is a website for Seniors that is filled with everything you need for healthy aging.
One of the valuable resources that is available on their site is an informative Guide to Seasonal Flu for Seniors that can be found by clicking on the link below.
A GUIDE TO SEASONAL FLU FOR SENIORS
The Flu is preventable with vaccines and other preventive measures. Please take the time to visit the website for
The National Council for Aging Care and speak with your provider regarding seasonal Flu vaccine.
Posted by Shari Smith on 2nd April, 2018 | Comments | Trackbacks | Permalink
Tags: Quadrivalent Flu Vaccine, Discount Vaccine Program, Vaccine Savings, Sanofi Fluzone, Discount Vaccines, Physicians Buying Group, Sanofi Flu Partners Program, Schedule your Flu Shot, Vaccine Group, Vaccine Group Purchasing Program, Sanofi Pasteur Flu Vaccine, Quadrivalent Influenza Vaccine, Savings on Adult Vaccines, Purchasing Program, Seasonal Flu, Seasonal Flu for Seniors, Discount Buying Opportunity, CASA Physicians Alliance, Discount Sanofi Vaccines, Discount Vaccine Buying Program, National Council for Aging Care
The Meningitis B Vaccine-Trumenba
THE MENINGITIS VACCINE (MCV4) THAT YOUR CHILD MAY HAVE RECEIVED DOES NOT COVER MENINGITIS B (1)
Here’s what you need to know about this disease
- There are 5 primary types of the bacteria that cause meningococcal disease, also known as meningitis, in the US- A, C, Y, W, and B (2)
- Since 2006, there have been vaccines (MCV4) that cover meningitis A, C, Y, and W, which your child may have recieved (1)
- Since 2014, vaccines for meningitis B, including TRUMENBA, have been approved (2)
- 40% of meningococcal disease cases among adolescents and young adults in the US are caused by meningitis B (3*)
- On average, 1 in 10 adolescents and young adults who develop meningitis B will die from it (3)
- Typical adolescent and young adult sharing behavior can spread the disease (4)
- It’s a bacterial infection that can cause inflammation of the membranes surrounding the brain and spinal cord (5)
- Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
- Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against divers group B strains has not been confirmed
IMPORTANT SAFETY INFORMATION
- Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
- Individuals with weakened immune systems may have a reduced immune response
- The most common adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills
- Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Tell your healthcare provider if you are pregnant, or plan to become pregnant
- Ask your healthcare provider about the risks and benefits of Trumenba. Only a healthcare provider can decide if Trumenba is right for you or your child
* Approximately 50-60 cases annually among 11 through 23 years during 2010-2012 . (2)
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.
Call 1-844-TRUMENBA (878-6362), 9 AM to 7 PM ET, Monday through Friday, for more information.
Visit TRUMENBA.com to learn more.
References: 1. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk of serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(22):608-612. 2. MacNeil JR, Rubin L, Folaranmi T, et al. Centers for Disease Control and Prevention. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1177. 3. Centers for Disease Control and Prevention. Epidemiology of serogroup B meningococcal disease, United States. Advisory Committee on Immunization Practices, October 30, 2014, Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-10/mening-02-MacNeil.pdf. 4. Soeters HM, MCNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college=Rhode Island, 2015. MMWR. 2015;64(22):606-607. 5. Centers for Disease Control and Prevention. Meningococcal disease: signs and symptoms: meningococcal meningitis. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/about/symptoms.html. Updated April 1, 2014. Accessed November 14, 2015.
Please see full Prescribing Information available from your healthcare provider.
Posted by Shari Smith on 5th February, 2018 | Comments | Trackbacks | Permalink
Tags: Trumenba MenB Vaccine, Trumenba Recommendation, ACIP MenB Recommendations, Discount Vaccine Program, Savings on Adolescent Vaccines, Trumenba Promotion, Trumenba Serogroup B vaccine, CASA Physicians Alliance, CASA Physicians Alliance - Trumenba Discount, Savings on Trumenba, Physicians Buying Group offering Discount on Trumenba Vaccine, Serogroup B Meningococcal MenB vaccine Trumenba, Trumenba Discounts, Discount Vaccine Buying Program, Vaccination Recommendation Trumenba, Trumenba Info, Vaccine Savings, Vaccine Group, Trumenba Two Dose Prescribing Information